.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH01_Vorinostat.Vorinostat .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XH01_Vorinostat.Vorinostat| name: | Vorinostat |
| ATC code: | L01XH01 | route: | oral |
| n-compartments | 1 |
Vorinostat is a histone deacetylase inhibitor used as an antineoplastic agent primarily for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. It is approved for use in several countries including the United States.
Pharmacokinetic parameters reported in adult patients with advanced cancer after oral administration. Data represent typical values in studied populations.
Wada, H, et al., & Iwatsuki, K (2012). Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma. The Journal of dermatology 39(10) 823–828. DOI:10.1111/j.1346-8138.2012.01554.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22506596
Ogawa, Y, et al., & Hotta, T (2016). A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma. International journal of hematology 103(1) 25–33. DOI:10.1007/s12185-015-1897-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26619834